U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226427) titled 'A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer' on Nov. 06.
Brief Summary: This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Platinum-resistant Ovarian Cancer
Intervention:
DRUG: MEN2501
Oral tablet
Recruitment Status: RECRUITING
Sponsor: Stemline Therapeutics, Inc.
Published by HT Digital Content Se...